Clinical characteristics and outcomes of the oldest old people with type 2 diabetes – perspective from a tertiary diabetes center in Thailand by unknown
RESEARCH ARTICLE Open Access
Clinical characteristics and outcomes of the
oldest old people with type 2 diabetes –
perspective from a tertiary diabetes center
in Thailand
Thewjitcharoen Yotsapon*, Krittiyawong Sirinate, Wanothayaroj Ekgaluck, Vongterapak Somboon,
Anuntakulnatee Tawee, Kittipoom Worawit, Nakasatien Soontaree and Himathongkam Thep
Abstract
Background: Advance in medicine has led to an increase in life expectancy of elderly diabetic patients especially
on the growing population called the “oldest old”, those in their mid-80s upwards. The aim of this study is to
describe clinical characteristics and outcomes of “oldest old” patients in a specialized diabetes center.
Methods: A retrospective review was conducted on medical records of type 2 diabetes who were older than
85 years at Theptarin hospital from September 2014 to August 2015.
Results: During the study period, there were 143 oldest old diabetic patients who visited our hospital regularly. Of
the 133 active follow-up patients (median time of follow-up 15 years, range 1–30 years), 70.7 % was female, the
mean age of onset was 68.3 ± 11.5 years and duration of diabetes was 20.1 ± 11.1 years. According to the Charlson
co-morbidity index (CCI), 35.3 % of patients were classified as having severe co-morbidities. The mean A1C, blood
pressure, LDL were 6.7 ± 1.1 %, 132/65 mmHg and 80 ± 29 mg/dl respectively. 66.9 % of patients had tight glycemic
control (A1C <7 %) while 12.0 % had poor control (A1C >8 %). Oral hypoglycemic agent (OHA) dual therapy was
the most common treatment (26.3 %) followed by OHA monotherapy (22.6 %), insulin alone (19.5 %), diet therapy
alone (12.7 %), and insulin plus OHA (8.3 %). Hypoglycemia was found in 10.5 % of patients in previous 12 months.
Diabetic retinopathy, chronic kidney disease, cardiovascular disease, and stroke were presented in 23.4, 54.9, 15.8,
18.0 % of patients, respectively. Among patients whose received diabetic medications and resulted in very low level
of A1C (A1C less than 6.0 %), only 20.0 % underwent deintensification.
Conclusions: Our results revealed that real-world clinical outcomes of extreme elderly diabetic patients were
diverse and being too “aggressive” diabetes treatment with older patients did occur frequently. Decision making in
older people with diabetes is complex as chronic co-morbidities are very common.
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Background
Over decades, Thailand has developed to become the
second largest economy in term of gross domestic prod-
uct (GDP) in Southeast Asia, and 10th in Asia [1]. At the
same time, Thailand has become an aging nation.
According to the United Nations projection [2], the pro-
portion of people aged over 65 years in Thailand will in-
crease from 10.5 % in 2015 to 26.6 % (17.6 million
people) in 2030, and 32.1 % (20.5 million people) in
2040. In the mid-1980s, the term ‘oldest old’ referring to
people aged 85 or older was introduced by gerontolo-
gists in an effort to focus attention on this growing seg-
ment of the population [3]. As the population continues
to age since the term ‘oldest old’ was originally coined, it
is important to note that the cut-off at age of 85 is fairly
arbitrary and largely serves to create consensus and uni-
formity between studies. With the combination of aging
population and diabetes epidemic, the number of elderly
with type 2 diabetes (T2DM) will continue to rise.
Generally, the goal of diabetic treatment in the elderly
is to maintain functional abilities and quality of life as
well as to prevent diabetic complications. However, eld-
erly patients have to cope not only with problems related
to the management and treatment of diabetes, but also
additional burden related to aging and associated co-
morbidities [4]. Older adults with diabetes are at greater
risk of other common geriatric syndromes such as de-
pression, cognitive impairment, urinary incontinence,
falls, polypharmacy, etc. [5–7]. These factors are respon-
sible for deviation from guideline of therapy. Most clinical
evidence on the management of diabetes was derived from
randomized controlled trials but the evidence from these
trials is often not applicable to older people as they are
usually excluded [8]. The risk of hypoglycemia from treat-
ments presents the greatest significant barrier to optimal
glycemic control for the very old patients [9]. Further-
more, the physiology of aging changes their responses to
therapy and other problems such as dementia, depression
and frailty have a significant impact on the treatment and
management of their diabetes [5].
The complexities of diabetes care associated with
aging will continue to dominate clinical practice in the
foreseeable future. Moreover, Decision making in older
people with diabetes is complex and factors other than
biomedical goals need to be addressed including co-
morbidity and life expectancy. However, data for the
oldest old group especially in diabetic patients are very
limited. Therefore, the aim of this study is to describe
the clinical characteristics and outcomes of oldest old
with diabetes in a specialized diabetes center.
Methods
We retrospectively reviewed medical records of all
T2DM with age more than 85 years who were treated
between September 2014 and August 2015 at Theptarin
hospital, Bangkok, Thailand. Patients who were regularly
follow-up at least 2 times during the study period
(duration of 12 months) were included. Exclusion cri-
teria included patients who were lost to follow-up in the
previous 12 months. Demographic data, recorded gly-
cated hemoglobin (A1C) in the previous 12 months,
lipid profiles, serum creatinine, previous history of acute
diabetic complications including hypoglycemia in the
previous 12 months, chronic diabetic complications, and
other co-morbidities during the study period were
retrieved. In the absence of these data in the charts, tele-
phone contact was attempted by diabetic nurse educa-
tors. Those who were diagnosed with diabetes when
they were ≥ 65 years of age are referred to as elderly-
onset diabetes and those diagnosed with diabetes at age
< 65 years are referred to as long-standing diabetes
group.
Retinopathy was detected with the regular dilated eye
examinations by ophthalmologists annually. Nephropa-
thy was defined as persistent proteinuria greater than
500 mg/24 h or microalbuminuria greater than 30 mg/
24 h confirmed on at least 2 occasions, 3–6 months
apart. Hypertension was defined as blood pressure >140/
90 mmHg and hypercholesterolemia was defined as low
density lipoprotein (LDL) cholesterol >100 mg/dL. For
A1C level, we defined very low as less than 6.0 %,
moderately low as 6.0 to 6.4 %, not low as 6.5 % or
greater, and high as greater than 8.0 %. Safe margin
of A1C was defined as all values that are neither low
nor high (6.5–8.0 %) [10, 11]. Mild hypoglycemia was
defined as hypoglycemia documented in the medical
records which did not require additional support. Se-
vere hypoglycemia was defined as hypoglycemia that
required assistance to recover (e.g. ambulance call-
out, hospitalization, supporter/relative assistance to
aid recovery).
The complexity of co-morbidities was determined by
the Charlson comorbidity index (CCI) which originally
was developed to predict the one-year mortality based
on comorbidity data [12]. This index score composed of
19 medical conditions and patients were divided into
three groups: mild, with CCI scores of 1–2; moderate,
with CCI scores of 3–4; and severe, with CCI scores ≥5.
Diabetic medication deintensification was defined as dis-
continuation or dosage reduction of any diabetic medi-
cation during the last 6 months of study period after
A1C level went below 6.5 %.
Setting and study population
Theptarin Hospital is a private hospital in the central
area of Bangkok and is one of the largest diabetes
centers in Bangkok with over 2000 registered diabetic
patients. Most diabetic patients are treated at diabetes
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clinic which has 12 diabetologists and a diabetes care
team that includes diabetes nurse educators, dietitians
and foot care specialists. Minority of elderly diabetic pa-
tients have regular follow-up by their primary physicians
or a geriatrician. This retrospective study is approved by
the Ethics board committee of Theptarin Hospital
(No.02/2015).
Statistical analysis
Continuous variables were presented as mean (SD) and
categorical variables were presented as proportions.
Comparisons between new-onset diabetes in elderly
group and long-standing diabetes group were done using
an unpaired Student’s t-test in continuous data and using
a Chi-square test in categorical data. P-value ≤ 0.05 was
considered statistically significant. All statistical analyses
were conducted using the Statistical Package for the Social
Sciences (version 17.0; SPSS, Chicago, IL, USA).
Results
There are 143 oldest old diabetic patients visited our
hospital regularly during the study period. The total
number of these patients comprised of 5.0 % of the total
2859 registered patients in our hospital at the same
period. Ten patients died from various medical illnesses
during studied. Of the remaining 133 active patients
(median time of follow-up 15 years, range 1–30 years),
70.7 % was female, the mean age of onset was 68.3 ±
11.5 years and duration of diabetes was 20.1 ± 11.1 years.
Of these, 84 patients (63.2 %) were diagnosed with dia-
betes at age ≥ 65 years and formed the elderly-onset
group (mean duration of diabetes 14.7 ± 8.3 years). The
other 49 patients were diagnosed with diabetes at age <
65 years and formed the long-standing diabetes group
(mean duration of diabetes 29.3 ± 9.1 years). Diabetic
retinopathy, nephropathy, cardiovascular disease, and
stroke were presented in 23.4, 54.9, 15.8, 18.0 %, respect-
ively. Multi-morbidity was highly prevalent in these pa-
tients. On average, patients experience 4 concurrent
chronic medical conditions. According to the Charlson
co-morbidity index (CCI), 42.9 % of patients were classi-
fied as having moderate co-morbidities and 35.3 % of pa-
tients were classified as having severe co-morbidities.
Cerebrovascular diseases were also prominent (18.0 %).
Diagnosed dementia was found in 22.6 % of patients
which almost half of them were bed-ridden. The demo-
graphic and general characteristics of the two patient
groups of patients are summarized in Table 1. Metabolic
controls and incidence of diabetic complications of both
groups of oldest old diabetic patients were also showed
in Table 1 and Fig. 1. Only the percentage of patients
with diabetic retinopathy was statistically significantly
higher in the long-standing diabetes group compared
with the new-onset diabetes in elderly group (P = 0.014).
During the study period, 125 patients (89 %) had A1C
levels measured on average of 3 times (range 1–5 times)
per year. The mean of A1C during the past 12 months
was 6.7 ± 1.1 %. 66.9 percents of patients had tight gly-
cemic control (A1C <7 %) while only 12.0 % of patients
had poorly controlled diabetes (HbA1c >8 %). Very low
level of A1C (less than 6.0 %), moderately low level of
A1C (6.0 to 6.4 %), safe margin of A1C (6.5 to 8.0 %)
were found in 23.3, 22.6, 39.8 %, respectively. The last
measurement of mean blood pressure and LDL were
132/65 mmHg and 80 ± 29 mg/dl, respectively. Eighty-
two percent of patients were on anti-hypertensive drugs
and 76.7 % of patients were taking statins at the time of
study. Regarding diabetic treatments, oral hypoglycemic
agent (OHA) dual therapy was the most common treat-
ment (26.3 %) followed by OHA monotherapy (22.6 %),
insulin alone (19.5 %), diet therapy alone (12.7 %), and
insulin plus OHA (8.3 %). For OHA-treated patients,
metformin was the most commonly prescribed diabetic
medication (38.3 %), followed by sulphonylurea (24.0 %),
and DPP4 inhibitor (DPP4i) (24.0 %). Hypoglycemia was
found in 10.5 % of patients in previous 12 months.
Among patients whose received diabetic medications
and resulted in very low level of A1C (A1C less than
6.0 %), only 20.0 % underwent deintensification. The de-
tails of diabetic medications deintensification according
to range of glycemic control were showed in Fig. 2. In
the past 12 months, there were 2 patients who experi-
enced severe hypoglycemia and 12 patients had symp-
tomatic hypoglycemia (total rate of symptomatic
hypoglycemia = 10.5 %). The occurrence of hypoglycemia
was highest in the insulin-treated patients as shown in
Fig. 3.
Discussions
The world population is getting older in both developed
and developing countries but this trend is occurring at a
much faster rate in developing countries. A population
is considered ‘aging’ when 10 % of the total population
is 60 or older, and 7 % of the population is 65 or older.
A society will turn into an ‘aged society’ and ‘superaged
society’ once the proportion aged 65 or over is greater
than 14 and 20 % of the population, respectively [2].
Thailand now stands in the forefront of high middle-
income countries will move from being an ‘aging’ to an
‘aged’ society in less than a decade from now, and to a
super-aged status in about half a decade. Among
ASEAN countries, Thailand ranks second after Singapore
in term of highest proportion of elderly people. This
demographic change will produce wide-ranging effects on
the country’s economy and social structure.
Frailty increases significantly with age. The ‘oldest old’
group (people aged 85 and older) therefore are usually
contains the frailest members of society, who require
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support from health and social services to maintain good
quality of life [13]. However, each individual varies widely
in terms of demography, social and health characteristics
[14]. Aging is unequal and is not a matter of chronological
age alone. Also, there is a pronounced sex imbalance with
women greatly outnumber men especially among the old-
est old. With advancing age, older patients suffer more
from various medical conditions including diabetes. Un-
fortunately, there is little evidence to guide recommenda-
tions for diabetes management in old age when issues of
multi-morbidity, polypharmacy, frailty and dementia co-
exist [10]. While older people tend to have normal hepatic
glucose output, aging is associated with declining pancre-
atic islet cell function and lower insulin levels [5]. Elderly
patients with diabetes mellitus can be divided into two
subgroups: elderly age-at-onset (or senile diabetes) and
younger age-at-onset (or long lasting diabetes) groups.
Those who develop type 2 diabetes in old age are more
likely to have near normal fasting glucose levels but sig-
nificant postprandial hyperglycemia [15, 16]. In contrast
to the new-onset diabetes in elderly, elderly with long-
standing diabetes tend to develop more diabetic complica-
tions and require particular attention. As a result, the
differences of demographic and clinical characteristics of




diabetes (N = 49)
Elderly-onset
diabetes (N = 84)
p-value
Age (yrs) 87.7 ± 3.0 87.2 ± 3.0 88.1 ± 2.9 0.083
Female (%) 94 (70.7 %) 38 (77.6 %) 56 (66.7 %) 0.186
DM duration (yrs) 20.1 ± 11.1 29.3 ± 9.1 14.7 ± 8.3 <0.001
Age of onset (yrs) 68.3 ± 11.5 57.8 ± 9.3 74.3 ± 7.7 <0.001
Follow-up time (yrs) 15.1 ± 7.8 18.3 ± 8.3 13.2 ± 6.8 <0.001
BMI (kg/m2) 23.4 ± 4.2 23.4 ± 4.0 23.5 ± 4.4 0.971
Smoking status:
-Never 116 (87.2 %) 45 (91.8 %) 71 (84.5 %)
-Ex-smokers 15 (11.3 %) 4 (8.2 %) 11 (13.1 %)
-Current 2 (1.5 %) 0 (0 %) 2 (2.4 %)
Comorbidities
-Myocardial Infarction 21 (15.8 %) 10 (20.4 %) 12 (14.2 %)
-Stroke 24 (18.0 %) 10 (20.4 %) 14 (16.7 %)
-Peripheral arterial diseasea 26 (23.4 %) 9 (22.0 %) 17 (21.3 %)
-Chronic kidney disease 73 (54.9 %) 25 (51.0 %) 48 (57.1 %)
-Cancer 8 (6.0 %) 2 (4.1 %) 6 (7.1 %)
-Dementia 30 (22.6 %) 12 (24.5 %) 18 (21.4 %)
Charlson comorbidity index
-Mild (1–2) 29 (21.8 %) 10 (20.4 %) 19 (22.6 %)
-Moderate (3–4) 57 (42.9 %) 21 (42.9 %) 36 (42.9 %)
-Severe (≥5) 47 (35.3 %) 18 (36.7 %) 29 (34.5 %)
HbA1c (%) 6.7 ± 1.1 6.8 ± 1.0 6.7 ± 1.1 0.454
Frequency of HbA1c testings (times per year) 3.1 ± 1.4 3.2 ± 1.4 3.1 ± 1.4 0.714
Blood pressure (mmHg) 132 ± 16/65 ± 11 131 ± 16/64 ± 13 133 ± 15/67 ± 9 0.582
LDL (mg/dL) 80 ± 29 81 ± 34 79 ± 26 0.779
Diabetic retinopathy (%) b 22 (23.4 %) 14 (37.8 %) 8 (14.0 %) 0.014
Pattern of diabetes treatment
-Diet control alone 17 (12.8 %) 4 (8.2 %) 13 (15.5 %) 0.028
-Oral hypoglycemic agents 79 (59.4 %) 23 (46.9 %) 56 (66.5 %) 0.031
-Insulin therapy 37 (27.8 %) 22 (44.9 %) 15 (18.0 %) 0.013
aData were available in 111 patients
bData were available in 94 patients
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these two groups lead to complexity in generalization of
treatment or adherence to guideline. Moreover, most
recommendations and guidelines tend to focus on a single
disease rather than taking into account of managing
chronic illness of aging populations. A recent global sur-
vey among leading worldwide diabetologists, the results
from an example case of the oldest old revealed that “risk
of hypoglycemia from treatment”, “life expectancy”, and
“important comorbidities” were ranked among the top
three parameters when set personalized target A1C [17].
The median target A1C had been proposed at 8.0 %
(range 6.5–9.0 %) for the oldest old example case.
In the present study, there were heterogeneities of
health status of oldest old diabetic patients and varieties
of diabetes care patterns among diabetologists. About
13 % of oldest old diabetic patients especially in senile
diabetes group can possibly be effectively managed with
diet only. Even though almost 80 % of elderly-onset
diabetic patients in our cohort had moderate to severe
comorbidity conditions, their glycemic control were rela-
tively better when compared with long-standing diabetic
patients. The possible reasons might be explained by the
benign nature of new-onset diabetes in elderly [5] and
also various comorbidity conditions especially chronic
kidney diseases in these patients might make patients
more aware of eating habits.
Approximately one fourth of patients especially in long
lasting diabetes group were on insulin treatment (mostly
insulin analog). Although many insulin-based regimens
have been used safely in elderly patients, hypoglycemia is
a concern and presents a challenge for obtaining optimal
glycemic control [18]. The main reasons for our diabetol-
ogists to use insulin in extreme elderly are comorbid con-
ditions of patients which precluded from use of oral
medications and failure of oral medications in bringing
glycemic control to target. In our study, we found
that symptomatic hypoglycemia tend to occur with
insulin-treated patients. Mixed split insulin regimen
was associated with the highest incidence of
hypoglycemia. This finding might come from variable
eating patterns of some elderly patients. In those pa-
tients, a basal-plus or basal-bolus regimen might be
better options in patients who failed basal insulin
regimen. As age, frailty, insulin treatment, and chronic
kidney disease are known risk factors for hypoglycemia
and hypoglycemic symptoms may be mistaken for other
conditions associated more commonly with advanced
ages, strategies to prevent hypoglycemia in very old pa-
tients should be emphasized. Focus should be on educat-
ing caregivers to recognize the signs and symptoms of
hypoglycemia and to frequently perform home blood glu-
cose monitoring.
Fig. 1 Range of glycemic control in oldest old diabetes patients
Fig. 2 Rate of Medications Deintensification according to range of glycemic control
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For OHA-treated patients, metformin was commonly
prescribed diabetic medication. This finding is contrast
with a recent study from China which showed sulphony-
lurea was the most commonly used oral drug for elderly
Chinese patients [19]. Although some concerns about an
increase in the risk of metformin-associated lactic acid-
osis in very old patients and lack of data in this extreme
aging population, the risk of lactic acidosis is very rare
and preventable [20, 21]. In view of favorable profiles of
metformin, it would continue to be used as a first line
treatment in oldest old diabetes patients with adjusted
dosage to renal function. In patients who are using
sulfonylurea drugs, the presence and frequency of
hypoglycemia should be evaluated at each visit. In
our study, we also found that DPP-4 inhibitors were
prescribed as the second most common drugs for the
oldest old patients. A recent retrospective study on
DDP-4 inhibitors prescribed to elderly diabetes pa-
tients (median age 70 years, range 60–92 years) found
that median A1C improved from 8.3 to 7.4 % and DDP-4
inhibitors treated patients had a lower rate of documented
hypoglycemia than the non-DPP-4 inhibitors treated
group (3 vs. 8 %) [22]. Therefore, DPP-4 inhibitors would
be an attractive choice for oldest old patients for its lower
rate of hypoglycemia and neutral weight effects. Another
class of adjuvant OHA which was popularly used in East
Asian countries but not in our patients is alpha-
glucosidase inhibitors (α-GI). Even though α-GI is an an-
other attractive choice in elderly patients for low risk of
hypoglycemia, gastrointestinal side effects and its clinical
response which depends on preserved β-cell function limit
its widespread use [23]. However, a recent population-
based nationwide cohort study from Taiwan showed that
α-GI (Acarbose) use reduced the risk of colorectal cancer
in a dose-dependent manner [24]. The potential mechan-
ism of this finding might be explained by the effects of
Acarbose in reducing colonic transit time and changes in
the fecal concentration of bile acids [25]. This interesting
finding would deserve more study in a prospective study
in elderly patients.
Older adults with diabetes are also at high risk for
polypharmacy, functional disabilities, and common geri-
atric syndromes that include cognitive impairment, de-
pression, urinary incontinence, falls, and persistent pain.
Diabetes and its comorbidities are associated with
Alzheimer’s disease, vascular dementia, and mixed de-
mentia which the prevalence of dementia ranges from
18-38 % among those aged 85 and older, and from 28-
44 % among those aged 90 and older [26, 27]. The in-
creasing prevalence of mixed pathologies of dementia
and susceptibility to side effects of treated medications
among the oldest old make a difficulty in treatment of
dementia in this age group. In our cohort, we found that
more than one fifth of patients suffered from dementia
and half of these patients had severe dementia with al-
most bed-ridden status. In theory, targets in frail older
people with diabetes should focus on short-term day to
day blood glucose levels to avoid hypoglycemia, rather
than basing diabetes care around a long term A1C strat-
egy. However, in a real-world setting, a large proportion
of these patients are still receiving aggressive diabetic
medications from specialists. This finding is similar to a
recent study in US Veterans Health Administration
which reported that only 27 % of patients who already
had very low A1C or blood pressure underwent medica-
tion deintensification [28]. Therefore, overtreatment of
diabetes in extreme age patients who had low life ex-
pectancy still prevails as showed in our study. Encour-
aging treating physicians to consider deintensification
when appropriate should be focused as one of clinical
performance index in diabetes care.
For chronic diabetic complications, our data also clearly
showed that diabetic retinopathy (DR) was much more
common in long-standing diabetes than elderly-onset dia-
betes (38 VS. 14 %). A recent study of DR prevalence in
elderly Chinese population (mainly elderly-onset diabetes)
Fig. 3 Incidence of symptomatic hypoglycemia in oldest old diabetes patients according to type of treatments
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revealed similar prevalence at around 16 % [29]. There-
fore, even though the prevalence of DR is relatively low in
elderly patients but long-standing diabetes patients suffer
much higher rate due to long duration of diabetes. Timely
screening and early treatment are still the basis of prevent-
ing blindness from diabetic retinopathy. Another medical
condition which revealed a very high rate in oldest old
patients was chronic kidney disease (CKD). The clinical
and pathologic heterogeneity of nephropathy in type 2
diabetes especially in elderly patients reflect various causes
of chronic kidney disease in this age group apart from
metabolic consequence of diabetes. Optimal care for these
patients is complex and best managed using comprehen-
sive multi-factorial risk-reduction strategies with multidis-
ciplinary team-based care [30-31]. Diabetes care should be
individualized based on frailty, life expectancy, and co-
morbid conditions.
The strengths of this study are that patients were
followed up by the same diabetologists for a long period
of time enabling us to collect details data and that this
cohort study is the first comprehensive report on oldest
old diabetes patients in Thailand. However, limitations
do exist. First, the retrospective nature of the study re-
sulted in relatively incomplete and missing data on some
aspects such as neuropathy evaluation. Second, we used
medical records to represent drug prescriptions rather
than the actual dispensing data and also there was no data
on patient adherence to treatment. Third, our study came
from a single hospital in a private setting located in the
central of Bangkok which limits the generalizability of the
findings.
Conclusions
In conclusion, managing the increasing population of ex-
treme elderly people with diabetes represents a significant
challenge. Our study revealed that real-world clinical out-
comes of these diabetic patients were diverse and being
too “aggressive” on diabetes treatment in older patients
occurred frequently. Decision making in older people with
diabetes is complex as chronic co-morbidities are very
common in this group of patients. It is a challenge for pol-
icy makers in dealing with growing oldest old with dia-
betes population. Results from this retrospective study
suggest opportunities to look into reducing overtreatment
and rethinking about quality versus quality of life. This
study also brings out the importance of recognizing het-
erogeneity of the population when it comes to treatment
decision.
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